vs
AIM ImmunoTech Inc.（AIM）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是AIM ImmunoTech Inc.的117785.4倍（$2.5B vs $21.0K）。艾伯维净利率更高（35.5% vs -19881.0%，领先19916.4%）。艾伯维同比增速更快（83.2% vs -53.3%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
AIM vs ARGX — 直观对比
营收规模更大
ARGX
是对方的117785.4倍
$21.0K
营收增速更快
ARGX
高出136.5%
-53.3%
净利率更高
ARGX
高出19916.4%
-19881.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $2.5B |
| 净利润 | $-4.2M | $877.2M |
| 毛利率 | — | 89.5% |
| 营业利润率 | -14057.1% | 28.9% |
| 净利率 | -19881.0% | 35.5% |
| 营收同比 | -53.3% | 83.2% |
| 净利润同比 | 30.0% | 1.3% |
| 每股收益（稀释后） | $-6.46 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMARGX
| Q4 25 | $21.0K | $2.5B | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $25.0K | $1.8B | ||
| Q1 25 | $16.0K | — | ||
| Q4 24 | $45.0K | $1.4B | ||
| Q3 24 | $35.0K | — | ||
| Q2 24 | $50.0K | $901.9M | ||
| Q1 24 | $40.0K | — |
净利润AIMARGX
| Q4 25 | $-4.2M | $877.2M | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.8M | $414.8M | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $-6.0M | $865.6M | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.8M | $-32.5M | ||
| Q1 24 | $-5.8M | — |
毛利率AIMARGX
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
营业利润率AIMARGX
| Q4 25 | -14057.1% | 28.9% | ||
| Q3 25 | -9411.5% | — | ||
| Q2 25 | -10584.0% | 19.2% | ||
| Q1 25 | -22618.8% | — | ||
| Q4 24 | -13011.1% | 8.7% | ||
| Q3 24 | -12825.7% | — | ||
| Q2 24 | -7388.0% | -15.4% | ||
| Q1 24 | -14335.0% | — |
净利率AIMARGX
| Q4 25 | -19881.0% | 35.5% | ||
| Q3 25 | -12630.8% | — | ||
| Q2 25 | -11176.0% | 23.4% | ||
| Q1 25 | -23156.3% | — | ||
| Q4 24 | -13260.0% | 64.1% | ||
| Q3 24 | -10571.4% | — | ||
| Q2 24 | -3672.0% | -3.6% | ||
| Q1 24 | -14542.5% | — |
每股收益（稀释后）AIMARGX
| Q4 25 | $-6.46 | $13.25 | ||
| Q3 25 | $1.57 | — | ||
| Q2 25 | $-3.68 | $6.32 | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-21.80 | $13.33 | ||
| Q3 24 | $-6.00 | — | ||
| Q2 24 | $-3.00 | $-0.55 | ||
| Q1 24 | $-0.12 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $3.5B |
| 总债务越低越好 | $4.5M | — |
| 股东权益账面价值 | $-9.8M | $7.3B |
| 总资产 | $5.8M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AIMARGX
| Q4 25 | $3.0M | $3.5B | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $835.0K | $2.1B | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $4.0M | $1.5B | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $10.1M | $1.4B | ||
| Q1 24 | $10.9M | — |
总债务AIMARGX
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | $11.0M | ||
| Q1 24 | $3.3M | — |
股东权益AIMARGX
| Q4 25 | $-9.8M | $7.3B | ||
| Q3 25 | $-6.1M | — | ||
| Q2 25 | $-6.5M | $6.1B | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-1.3M | $5.5B | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $6.1M | $4.3B | ||
| Q1 24 | $4.8M | — |
总资产AIMARGX
| Q4 25 | $5.8M | $8.7B | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $4.1M | $7.2B | ||
| Q1 25 | $6.2M | — | ||
| Q4 24 | $8.6M | $6.2B | ||
| Q3 24 | $13.6M | — | ||
| Q2 24 | $15.7M | $4.8B | ||
| Q1 24 | $16.2M | — |
负债/权益比AIMARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | 0.00× | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | — | $322.4M |
| 自由现金流率自由现金流/营收 | — | 13.0% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | — | $594.5M |
8季度趋势，按日历期对齐
经营现金流AIMARGX
| Q4 25 | $-2.0M | $323.3M | ||
| Q3 25 | $-5.1M | — | ||
| Q2 25 | $-1.5M | $361.8M | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-4.0M | $41.9M | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-3.0M | $-124.7M | ||
| Q1 24 | $-4.8M | — |
自由现金流AIMARGX
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $356.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $40.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-125.5M | ||
| Q1 24 | — | — |
自由现金流率AIMARGX
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 20.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | — |
资本支出强度AIMARGX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
现金转化率AIMARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
